Table 2.
Ongoing PARPi trials
| Drug company | Year opened | Phase | Name | NCT number | Status |
|---|---|---|---|---|---|
| Olaparib AztraZeneca | 2016 | II-III | Randomized, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients with TNBC and/or gBRCA. (PARTNER) | NCT03150576 | recruiting |
| 2014 | III | Olaparib as Adjuvant Treatment in Patients with Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA) | NCT02032823 | recruiting | |
| 2012 | I | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | active, not recruiting | |
| 2014 | Ib | A Phase lb Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02208375 | active, not recruiting | |
| 2013 | I | Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast And regional Lymph Nodes in Patients With Breast Cancer | NCT02227082 | recruiting | |
| 2010 | I-II | Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer | NCT01116648 | active, not recruiting | |
| 2016 | II | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | NCT02498613 | recruiting | |
| 2015 | I-II | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | NCT02484404 | recruiting | |
| 2016 | I-II | A Phase I/II Study of MEDI4736 (Anti-PD-Ll Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors | NCT02734004 | active, not recruiting | |
| 2017 | II | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | NCT03167619 | open, not yet recruiting | |
| Rucaparib Clovis Oncology | 2016 | II | A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (RUBY) | NCT02505048 | recruiting |
| 2016 | II | Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | Open in UK (ISRCTN 92154110 CRUK/12/034) | recruiting | |
| Veliparib AbbVie | 2016 | II | Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-Ll Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) | NCT02849496 | recruiting |
| 2016 | II | Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer | NCT02595905 | recruiting | |
| 2014 | A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer | NCT02163694 | recruiting | ||
| 2009 | II | A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers | NCT01009788 | active, not recruiting | |
| 2012 | II | A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | active, not recruiting | |
| Niraparib Tesaro | 2016 | I-II | Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer (TOPACIO) | NCT02657889 | recruiting |
| 2013 | III | A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician’s Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO) | NCT01905592 | active, not recruiting | |
| 2017 | II | A Feasibility Study of Niraparib for Advanced, BRCAl-like, HER2-negative Breast Cancer Patients: the ABC Study | NCT02826512 | open, not yet recruiting | |
| Talazoparib Pfizer | 2017 | I-Ib | A Phase lb/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors | NCT03330405 | recruiting |
| 2013 | III | A Phase 3, Open-label, Randomized Parallel, 2-arm, Multi-center Study Of Talazoparib(Bmn 673) Versus Physician’s Choice In Germline Brea Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease | NCT01945775 | active, not recruiting | |
| 2015 | II | A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation | NCT02282345 | recruiting |